|
Video: What is a Stock Split?
|
|
Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019. According to our Theravance Biopharma stock split history records, Theravance Biopharma has had 0 splits. | |
|
Theravance Biopharma (TBPH) has 0 splits in our Theravance Biopharma stock split history database.
Looking at the Theravance Biopharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Theravance Biopharma shares, starting with a $10,000 purchase of TBPH, presented on a split-history-adjusted basis factoring in the complete Theravance Biopharma stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/19/2014 |
|
End date: |
04/30/2024 |
|
Start price/share: |
$21.97 |
|
End price/share: |
$8.44 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-61.58% |
|
Average Annual Total Return: |
-9.16% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,842.38 |
|
Years: |
9.96 |
|
|
|
|
|